Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $20.00 by Analysts at Robert W. Baird

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price lowered by Robert W. Baird from $26.00 to $20.00 in a report issued on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the biotechnology company’s stock.

Several other research firms have also recently issued reports on ENTA. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JPMorgan Chase & Co. cut their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday, August 6th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. Finally, JMP Securities reissued a “market outperform” rating and set a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $8.60 on Tuesday. Enanta Pharmaceuticals has a one year low of $8.00 and a one year high of $17.80. The stock has a market cap of $182.23 million, a PE ratio of -1.57 and a beta of 0.56. The stock has a 50 day moving average price of $10.81 and a 200 day moving average price of $12.25.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of ENTA. State Board of Administration of Florida Retirement System acquired a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at $118,000. Vanguard Group Inc. grew its stake in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after buying an additional 134,292 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at $191,000. Farallon Capital Management LLC boosted its holdings in Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after purchasing an additional 70,000 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares during the period. 94.99% of the stock is owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.